Zappy Zapolin’s Psycheceutical Files Patent, Hopes Ketamine Topical Can Treat PTSD

January 26, 2023 · Benzinga

Lifesciences biotech company Psycheceutical Bioscience 

BWVI, of which Benzinga’s advisory council member Zappy Zapolin is Chief Visionary Officer, patented a topical ketamine formulation to treat PTSD.

The patent includes related methods using drug delivery technology NeuroDirect.

Psycheceutical CEO Chad Harman says NeuroDirect’s topical delivery system could potentially provide “new solutions and treatments for PTSD and other mental health conditions,” considering the disorder is in some cases associated with anxiety, depression and substance use disorder.

The system’s design would topically distribute neuro-active compounds to the back of the neck for immediate and sustained action on brain nerve endings.

The new formulations and treatment methods intend to reduce PTSD-related pain and symptoms with safe dosage control while reducing side effects such as hallucinations, nausea, lethargy and toxicity.

“Psycheceutical is driven to provide new hope for this debilitating disorder by employing cutting-edge technologies for the patients who need it most,” the company’s CMO, Julian Bailes, says. “We look forward to improving current mental health treatments while progressing the capabilities of the psychedelic pharmaceutical category.” (Full Story)

In category:Medical
Next Post

Psychedelics May Be Part of U.S. Medicine Sooner Than You Think

It came as a surprise to many when, on Feb. 3, Australian regulators announced that medicines containing the psychedelic substances MDMA and psilocybin can soon be used there to treat post-traumatic stress disorder (PTSD) and treatment-resistant depression, respectively. That decision makes Australia…
Read
Previous Post

Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin

Core One Labs' Akome Partners To Study Next-Gen Psychedelics A subsidiary of Core One Labs  CLABF has signed a contract with Fundació Bosh I Gimpera to begin second-phase studies evaluating the therapeutic potential of its bio-compounds (both alone and combined with psychedelic substances). The…
Read
Random Post

New Mexico Rolls Out ‘Yes & Know’ Cannabis Public Education Campaign

New Mexico is rolling out its first media campaign to educate the public about responsible cannabis use, the Associated Press reports. The “Yes & Know” campaign is centered around the phrase “Yes – cannabis is legal. Know – the rules,” and will…
Read
Random Post

Maine’s Biggest City Passes Legislation To Decriminalize Psychedelic Plants And Fungi

The City Council in Portland, Maine, has voted to deprioritize the local enforcement of laws against psychedelic plants and fungi, adopting a resolution on Monday that emphasizes treating the use and possession of all controlled substances as a public health…
Read
Random Post

Johns Hopkins University To Spend $10 Million Studying Medical Cannabis

A new multi-million dollar study at Johns Hopkins University aims to analyze how patients nationwide respond to medical cannabis treatments.  Johns Hopkins University, which championed one of the largest and most widely referenced studies on medical applications of psilocybin mushrooms,…
Read
Random Post

And The Winners Are…The Emerald Cup Awards 2023

On May 13, 2023, the 19th instalment of the Emerald Cup Awards brought together the absolute best California has to offer. Held at the Craneway Pavilion in Richmond, CA, the 45,000-square-foot venue was filled with some of the industry’s top…
Read